Medicenna Therapeutics Corp. Stock price
Equities
MDNA
CA58490H1073
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.86 CAD | +10.39% | +18.47% | +342.86% |
Sales 2024 * | - | Sales 2025 * | 583K 431K | Capitalization | 130M 95.67M |
---|---|---|---|---|---|
Net income 2024 * | -16M -11.82M | Net income 2025 * | -19M -14.03M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 222 x |
P/E ratio 2024 * |
-7.91
x | P/E ratio 2025 * |
-7.15
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.73% |
Latest transcript on Medicenna Therapeutics Corp.
1 day | +10.39% | ||
1 week | +18.47% | ||
Current month | +66.07% | ||
1 month | +52.46% | ||
3 months | +353.66% | ||
6 months | +389.47% | ||
Current year | +342.86% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 11-09-30 | |
Fahar Merchant
CEO | Chief Executive Officer | - | 15-02-01 |
David Hyman
DFI | Director of Finance/CFO | - | Feb. 13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Karen Dawes
BRD | Director/Board Member | 72 | 19-09-23 |
Albert Beraldo
BRD | Director/Board Member | - | 16-11-21 |
Fahar Merchant
CEO | Chief Executive Officer | - | 15-02-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.86 | +10.39% | 452,703 |
24-03-27 | 1.685 | +8.71% | 63,799 |
24-03-26 | 1.55 | +3.33% | 106,586 |
24-03-25 | 1.5 | -5.06% | 92,699 |
24-03-22 | 1.58 | +0.64% | 84,918 |
Delayed Quote Toronto S.E., March 28, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+342.86% | 86.34M | |
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |